查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1511933

基底細胞癌治療市場規模、佔有率和趨勢分析報告：按治療類型、地區和細分市場預測，2024-2030年

Basal Cell Carcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment Type, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 158 Pages | 商品交期: 2-10個工作天內

價格

基底細胞癌治療市場的成長與趨勢：

Grand View Research最新報告顯示，預計到2030年，全球基底細胞癌治療市場規模將達到59.3億美元，2024年至2030年複合年成長率為10.44%。

這個市場主要是由基底細胞癌盛行率的增加和老年人口的增加所推動的。歐洲皮膚癌基金會估計，基底細胞癌（BCC）的發生率呈增加趨勢，歐洲每年每10萬人中有50至80例新病例，澳洲每10萬人中有250例新病例。癌症患者數量的增加主要是由於總人口和老年人口的增加以及某些社會經濟因素造成的。

疾病診斷和治療的技術進步預計將對市場成長產生積極影響。先進的技術使皮膚科醫生能夠更準確地診斷患者並有效區分基底細胞癌和其他皮膚病變。例如，2024年，美國FDA核准了人工智慧驅動的光學光譜儀DermaSensor用於檢測皮膚癌，包括黑色素瘤、單細胞癌（SCC）和基底細胞癌（BCC）。這項技術可以幫助初級保健臨床醫生識別需要立即切片檢查或專科治療的患者，從而減少某些地區漫長的等待時間和皮膚科醫生的短缺。此類診斷工具的增加使用預計將提高未來的診斷和治療率，從而推動對用於治療基底細胞癌的藥物的需求。

此外，不斷成長的老年人口正在推動對基底細胞癌治療的需求，包括手術、放射治療、局部化療、內服藥物和化學換膚。發生基底細胞癌的主要原因是反覆暴露於紫外線 (UV) 輻射。老年人比年輕人更容易罹患基底細胞癌，因為他們接觸更多的紫外線。老年人皮膚癌（尤其是基底細胞癌）的風險增加，因為隨著老齡化和免疫系統的減弱，紫外線輻射和其他致癌物質更容易破壞 DNA。根據2023年發表在《老年腫瘤學雜誌》上的一項研究，美國每年有超過10萬名BCC患者在生命的最後一年接受治療。因此，預計老年人口的增加將在預測期內推動市場成長。

基底細胞癌治療報告亮點

  • 2023年，外科手術領域佔市場最大的收益佔有率。這是由於疾病的發生率和盛行率不斷增加，以及對安全有效的手術治療的高需求。
  • 在局部化療中，5-Fluorouracil（5-FU）細分市場在2023年佔據最大市場佔有率。這是由於開發並推出了用於治療 BCC 患者的新非專利藥 5-Fluorouracil(5-FU)。
  • 由於先進的醫療基礎設施、基底細胞癌盛行率的增加以及有利於新產品研發的法規環境等因素，北美在市場上佔據主導地位。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第 3 章：基底細胞癌治療市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 基底細胞癌治療市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章基底細胞癌治療市場：治療類型估計與趨勢分析

  • 全球基底細胞癌治療市場：治療型儀表板
  • 全球基底細胞癌治療市場：治療類型變異分析
  • 全球基底細胞癌治療市場：依治療類型和收益
  • 外科手術
  • 放射治療 (RT)
  • 病灶內注射
  • 局部化療
  • 口服藥物
  • 靜脈注射藥物
  • 化學換膚治療

第5章基底細胞癌治療市場：按治療類型分類的區域估計和趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第6章 競爭狀況

  • 公司/競爭對手分類
  • 參與企業概況
  • 財務概覽
  • 治療類型基準
  • 2023 年企業市場佔有率分析
  • 策略規劃
  • 公司簡介
    • Bausch Health Companies Inc.
    • Almirall, SA
    • Genentech, Inc.（Subsidiary of F. Hoffmann-La Roche AG）
    • Novartis AG.
    • Regeneron Pharmaceuticals Inc.
    • Dr Reddy's Laboratories.
    • Taro Pharmaceuticals Ltd.
    • Accord Healthcare Limited（Subsidiary of Intas Pharmaceuticals）
Product Code: GVR-4-68040-170-1

Basal Cell Carcinoma Treatment Market Growth & Trends:

The global basal cell carcinoma treatment market size is anticipated to reach USD 5.93 billion by 2030, growing at a CAGR of 10.44% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the increasing prevalence of basal cell carcinoma and the rising geriatric population. The European Skin Cancer Foundation estimates that the incidence of basal cell carcinoma (BCC) is 50 to 80 new cases per 100,000 people in Europe and 250 cases per 100,000 people in Australia annually, with an increasing trend. The increase in the number of cancer cases can primarily be attributed to the growing overall & geriatric population and certain socioeconomic factors.

Technological advancement in the diagnosis and treatment of disease is anticipated to positively impact market growth. With advanced technologies, dermatologists can more accurately diagnose patients and effectively differentiate basal cell carcinoma from other skin lesions. For instance, in 2024, the U.S. FDA approved DermaSensor, an AI-powered light spectroscopy instrument for detecting skin cancer, including melanoma, single cell carcinoma (SCC), and basal cell carcinoma (BCC). This technique can help primary care clinicians identify patients who require rapid attention for a biopsy and specialist care, thereby alleviating high wait times and the shortage of dermatologists in certain places. The growing use of such diagnostic tools is expected to increase the diagnostic and treatment rates in the future, driving demand for medicines used for the treatment of basal cell carcinoma.

Furthermore, the increase in the geriatric population is driving the demand for treatment of BCC, including surgery, radiotherapy, topical chemotherapy, oral medications, and chemical peeling. The main cause of developing BCC is repeated exposure to Ultraviolet (UV) light. The elderly population has a higher chance of acquiring BCC than younger people as they have been exposed to UV rays for longer during their lifetime. Due to aging and reduced immune system function, UV radiation and other carcinogenic factors can break the DNA more easily, increasing the risk of skin cancer, especially BCC, in older persons. According to a study published in the Journal of Geriatric Oncology in 2023, over 100,000 patients with BCC are treated annually in their final year of life in the U.S. However, clinical practice guidelines hardly ever take age & comorbidities into account. Thus, a growing geriatric population is expected to drive market growth during the forecast period.

Basal Cell Carcinoma Treatment Report Highlights:

  • The surgery segment held the largest revenue share of the market in 2023. This can be attributed to the increasing incidence and prevalence of disease and the high demand for surgery for treatment owing to high safety and efficacy.
  • In topical chemotherapy, the 5-fluorouracil (5-FU) segment held the largest share of the market in 2023. This can be attributed to the development and launch of a novel generic version of 5-fluorouracil (5-FU) to treat BCC patients.
  • North America dominated the market owing to factors such as advanced healthcare infrastructure, increasing prevalence of basal cell carcinoma, and favorable regulatory environment for R&D of novel products.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment Type
    • 1.2.2. Regional scope
    • 1.2.3. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment Type Outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Basal Cell Carcinoma Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of target diseases
      • 3.2.1.2. Technological advancements
      • 3.2.1.3. Rising geriatric population
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Adverse effects associated with treatment.
      • 3.2.2.2. High cost of treatment
  • 3.3. Basal Cell Carcinoma Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Basal Cell Carcinoma Treatment Market: Treatment Type Estimates & Trend Analysis

  • 4.1. Global Basal Cell Carcinoma Treatment Market: Treatment Type Dashboard
  • 4.2. Global Basal Cell Carcinoma Treatment Market: Treatment Type Movement Analysis
  • 4.3. Global Basal Cell Carcinoma Treatment Market By Treatment Type, Revenue
  • 4.4. Surgery
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Mohs Surgery
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Surgical Excision
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Electrodesiccation and Curettage (ED&C)
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Radiotherapy (RT)
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Intralesional Injections
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Topical Chemotherapy
    • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.7.2. 5-fluorouracil (5-FU)
      • 4.7.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.7.3. Tirbanibulin (Klisyri)
      • 4.7.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.7.4. Imiquimod (Zyclara)
      • 4.7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Oral Medications
    • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.8.2. Vismodegib (Erivedge)
      • 4.8.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.8.3. Sonidegib (Odomzo)
      • 4.8.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. Intravenous Medications
    • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10. Chemical Peeling Treatment
    • 4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million).

Chapter 5. Basal Cell Carcinoma Treatment Market: Regional Estimates & Trend Analysis By Treatment Type

  • 5.1. Regional Dashboard
  • 5.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 5.3. North America
    • 5.3.1. U.S.
      • 5.3.1.1. Key country dynamics
      • 5.3.1.2. Regulatory framework/ reimbursement structure
      • 5.3.1.3. Competitive scenario
      • 5.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.3.2. Canada
      • 5.3.2.1. Key country dynamics
      • 5.3.2.2. Regulatory framework/ reimbursement structure
      • 5.3.2.3. Competitive scenario
      • 5.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.3.3. Mexico
      • 5.3.3.1. Key country dynamics
      • 5.3.3.2. Regulatory framework/ reimbursement structure
      • 5.3.3.3. Competitive scenario
      • 5.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4. Europe
    • 5.4.1. UK
      • 5.4.1.1. Key country dynamics
      • 5.4.1.2. Regulatory framework/ reimbursement structure
      • 5.4.1.3. Competitive scenario
      • 5.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Germany
      • 5.4.2.1. Key country dynamics
      • 5.4.2.2. Regulatory framework/ reimbursement structure
      • 5.4.2.3. Competitive scenario
      • 5.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. France
      • 5.4.3.1. Key country dynamics
      • 5.4.3.2. Regulatory framework/ reimbursement structure
      • 5.4.3.3. Competitive scenario
      • 5.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Italy
      • 5.4.4.1. Key country dynamics
      • 5.4.4.2. Regulatory framework/ reimbursement structure
      • 5.4.4.3. Competitive scenario
      • 5.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5. Spain
      • 5.4.5.1. Key country dynamics
      • 5.4.5.2. Regulatory framework/ reimbursement structure
      • 5.4.5.3. Competitive scenario
      • 5.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.6. Denmark
      • 5.4.6.1. Key country dynamics
      • 5.4.6.2. Regulatory framework/ reimbursement structure
      • 5.4.6.3. Competitive scenario
      • 5.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.7. Sweden
      • 5.4.7.1. Key country dynamics
      • 5.4.7.2. Regulatory framework/ reimbursement structure
      • 5.4.7.3. Competitive scenario
      • 5.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.8. Norway
      • 5.4.8.1. Key country dynamics
      • 5.4.8.2. Regulatory framework/ reimbursement structure
      • 5.4.8.3. Competitive scenario
      • 5.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Asia Pacific
    • 5.5.1. Japan
      • 5.5.1.1. Key country dynamics
      • 5.5.1.2. Regulatory framework/ reimbursement structure
      • 5.5.1.3. Competitive scenario
      • 5.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.2. China
      • 5.5.2.1. Key country dynamics
      • 5.5.2.2. Regulatory framework/ reimbursement structure
      • 5.5.2.3. Competitive scenario
      • 5.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.3. India
      • 5.5.3.1. Key country dynamics
      • 5.5.3.2. Regulatory framework/ reimbursement structure
      • 5.5.3.3. Competitive scenario
      • 5.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.4. Australia
      • 5.5.4.1. Key country dynamics
      • 5.5.4.2. Regulatory framework/ reimbursement structure
      • 5.5.4.3. Competitive scenario
      • 5.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.5. South Korea
      • 5.5.5.1. Key country dynamics
      • 5.5.5.2. Regulatory framework/ reimbursement structure
      • 5.5.5.3. Competitive scenario
      • 5.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.6. Thailand
      • 5.5.6.1. Key country dynamics
      • 5.5.6.2. Regulatory framework/ reimbursement structure
      • 5.5.6.3. Competitive scenario
      • 5.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Latin America
    • 5.6.1. Brazil
      • 5.6.1.1. Key country dynamics
      • 5.6.1.2. Regulatory framework/ reimbursement structure
      • 5.6.1.3. Competitive scenario
      • 5.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.6.2. Argentina
      • 5.6.2.1. Key country dynamics
      • 5.6.2.2. Regulatory framework/ reimbursement structure
      • 5.6.2.3. Competitive scenario
      • 5.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. MEA
    • 5.7.1. South Africa
      • 5.7.1.1. Key country dynamics
      • 5.7.1.2. Regulatory framework/ reimbursement structure
      • 5.7.1.3. Competitive scenario
      • 5.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.2. Saudi Arabia
      • 5.7.2.1. Key country dynamics
      • 5.7.2.2. Regulatory framework/ reimbursement structure
      • 5.7.2.3. Competitive scenario
      • 5.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.3. UAE
      • 5.7.3.1. Key country dynamics
      • 5.7.3.2. Regulatory framework/ reimbursement structure
      • 5.7.3.3. Competitive scenario
      • 5.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.7.4. Kuwait
      • 5.7.4.1. Key country dynamics
      • 5.7.4.2. Regulatory framework/ reimbursement structure
      • 5.7.4.3. Competitive scenario
      • 5.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Company/Competition Categorization
  • 6.2. Participant Overview
  • 6.3. Financial Overview
  • 6.4. Treatment Type Benchmarking
  • 6.5. Company Market Share Analysis, 2023
  • 6.6. Strategy Mapping
  • 6.7. Company Profiles
    • 6.7.1. Bausch Health Companies Inc.
      • 6.7.1.1. Company overview
      • 6.7.1.2. Financial performance
      • 6.7.1.3. Product benchmarking
      • 6.7.1.4. Strategic initiatives
    • 6.7.2. Almirall, S.A.
      • 6.7.2.1. Company overview
      • 6.7.2.2. Financial performance
      • 6.7.2.3. Product benchmarking
      • 6.7.2.4. Strategic initiatives
    • 6.7.3. Genentech, Inc. (Subsidiary of F. Hoffmann-La Roche AG)
      • 6.7.3.1. Company overview
      • 6.7.3.2. Financial performance
      • 6.7.3.3. Product benchmarking
      • 6.7.3.4. Strategic initiatives
    • 6.7.4. Novartis AG.
      • 6.7.4.1. Company overview
      • 6.7.4.2. Financial performance
      • 6.7.4.3. Product benchmarking
      • 6.7.4.4. Strategic initiatives
    • 6.7.5. Regeneron Pharmaceuticals Inc.
      • 6.7.5.1. Company overview
      • 6.7.5.2. Financial performance
      • 6.7.5.3. Product benchmarking
      • 6.7.5.4. Strategic initiatives
    • 6.7.6. Dr Reddy's Laboratories.
      • 6.7.6.1. Company overview
      • 6.7.6.2. Financial performance
      • 6.7.6.3. Product benchmarking
      • 6.7.6.4. Strategic initiatives
    • 6.7.7. Taro Pharmaceuticals Ltd.
      • 6.7.7.1. Company overview
      • 6.7.7.2. Financial performance
      • 6.7.7.3. Product benchmarking
      • 6.7.7.4. Strategic initiatives
    • 6.7.8. Accord Healthcare Limited (Subsidiary of Intas Pharmaceuticals)
      • 6.7.8.1. Company overview
      • 6.7.8.2. Financial performance
      • 6.7.8.3. Product benchmarking
      • 6.7.8.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America basal cell carcinoma market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 4 U.S. basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 5 Canada basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 6 Mexico basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 7 Europe basal cell carcinoma market, by region, 2018 - 2030 (USD Million)
  • Table 8 Europe basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 9 Germany basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 10 UK basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 11 France basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 12 Italy basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 13 Spain basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 14 Denmark basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 15 Sweden basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 16 Norway basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 17 Asia Pacific basal cell carcinoma market, by region, 2018 - 2030 (USD Million)
  • Table 18 Asia Pacific basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 19 China basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 20 Japan basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 21 India basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 22 South Korea basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 23 Australia basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 24 Thailand basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 25 Latin America basal cell carcinoma market, by region, 2018 - 2030 (USD Million)
  • Table 26 Latin America basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 27 Brazil basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 28 Argentina basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 29 MEA basal cell carcinoma market, by region, 2018 - 2030 (USD Million)
  • Table 30 MEA basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 31 South Africa basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 32 Saudi Arabia basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 33 UAE basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)
  • Table 34 Kuwait basal cell carcinoma market, By treatment type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Basal cell carcinoma treatments market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment.
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Treatment type segment snapshot
  • Fig. 10 Competitive landscape snapshot
  • Fig. 11 Parent market (USD Billion)
  • Fig. 12 Market dynamics
  • Fig. 13 Porter's five forces analysis
  • Fig. 14 PESTLE analysis
  • Fig. 15 Basal cell carcinoma treatment market: Treatment type outlook key takeaways
  • Fig. 16 Basal cell carcinoma treatment market: Treatment type movement analysis
  • Fig. 17 Surgery market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Mohs surgery market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Tumor removal procedures (including skin cancer)
  • Fig. 20 Surgical excision market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Electrodesiccation and Curettage (ED&C) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Radiotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Intralesional injections market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Topical chemotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 5-fluorouracil (5-FU) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Tirbanibulin (Klisyri) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Imiquimod (Zyclara) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Oral medications market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Vismodegib (Erivedge) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Sonidegib (Odomzo) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Intravenous medications market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Chemical peeling treatment minimally invasive procedures, 2018 - 2030 (USD Million)
  • Fig. 33 Chemical peeling treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Basal cell carcinoma treatment market revenue, by region, 2023 & 2030 (USD Million)
  • Fig. 35 Regional marketplace: Key takeaways
  • Fig. 36 Regional marketplace: Key takeaways
  • Fig. 37 North America basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Key country dynamics
  • Fig. 39 U.S. basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Key country dynamics
  • Fig. 41 Canada basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 Mexico basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Regulatory framework
  • Fig. 45 Europe basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 Key country dynamics
  • Fig. 47 UK basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Germany basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 France basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Key country dynamics
  • Fig. 53 Spain basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 Italy basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 56 Key country dynamics
  • Fig. 57 Denmark basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 Sweden basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Norway basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 62 Rest of Europe basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 63 Asia Pacific basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 Japan basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 66 Japan pharmaceutical registration
  • Fig. 67 Key country dynamics
  • Fig. 68 China basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 69 Regulatory details: China
  • Fig. 70 Key country dynamics
  • Fig. 71 India basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 72 Registration details: India
  • Fig. 73 Key country dynamics
  • Fig. 74 Australia basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 75 Drug pricing: Australia
  • Fig. 76 Contribution of PBS by disease
  • Fig. 77 Key country dynamics
  • Fig. 78 Thailand basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 South Korea basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 81 Reimbursement scenario: South Korea
  • Fig. 82 Rest of Asia Pacific basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 83 Latin America basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Brazil basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 Argentina basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 88 Argentina pharmaceuticals registration details
  • Fig. 89 Argentina pharmaceuticals reimbursement details
  • Fig. 90 Rest of Latin America basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 91 MEA basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 92 Key country dynamics
  • Fig. 93 South Africa basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 94 Regulatory framework: South Africa
  • Fig. 95 Regulatory framework: South Africa drug registration fees
  • Fig. 96 Key country dynamics
  • Fig. 97 Saudi Arabia basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 98 Key country dynamics
  • Fig. 99 UAE basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 100 Key country dynamics
  • Fig. 101 Kuwait basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 102 Regulatory framework: Kuwait
  • Fig. 103 Rest of MEA basal cell carcinoma treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 104 Market participant categorization
  • Fig. 105 Heat map analysis
  • Fig. 106 Strategic framework